How does nintedanib work?
NINTEDANIB IS A MULTI-TARGETED TYROSINE KINASE INHIBITOR THAT WORKS BY INHIBITING PATHWAYS INVOLVED IN THE PATHOGENESIS OF ILDs1-3
Explore the interactive MOA of nintedanib in 3D
See how common pathogenic pathways to pulmonary fibrosis are shared among different ILDs and how nintedanib works to inhibit key pathways involved in lung fibrosis. Select the chapters and labels to learn more. Click and drag to rotate and scroll to zoom.1,4-6
The MOA is based on preclinical data and provided for illustrative purposes only.
WATCH THE VIDEO TO LEARN HOW NINTEDANIB WORKS TO INHIBIT KEY PATHWAYS INVOLVED IN LUNG FIBROSIS1-3
Document ID: PC-SA-102502 | Expiry Date: 24/08/2026
NINTEDANIB IS A MULTITARGETED TYROSINE KINASE INHIBITOR (TKI) THAT INHIBITS PATHWAYS INVOLVED IN THE PATHOGENESIS OF ILDS1-3
Nintedanib is a multitargeted TKI that inhibits key pathways involved in lung fibrosis1
Nintedanib is not an
immunosuppressant.1
Nintedanib binds intracellularly to key receptors to block downstream signaling cascades1,3
Nintedanib has been shown to inhibit fibroblast proliferation, migration, and fibroblast-to-myofibroblast transformation1,3
NINTEDANIB BINDS INTRACELLULARLY TO KEY RECEPTORS TO BLOCK DOWNSTREAM SIGNALING CASCADES1,3
The MOA is based on preclinical data and provided for illustrative purposes only.1
NINTEDANIB AFFECTS THE UNDERLYING PATHWAYS INVOLVED IN FIBROTIC TISSUE REMODELING1-3,7
The MOA is based on preclinical data and provided for illustrative purposes only.1
FGFR, fibroblast growth factor receptor; ILD, interstitial lung disease; MOA, mechanism of action; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor.
References
-
OFEV® (nintedanib) Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2022.
-
Hilberg F et al. Cancer Res. 2008;68(12):4774-4782.
-
Wollin L et al. J Pharmacol Exp Ther. 2014;349(2):209-220.
-
Wells AU et al. Eur Respir J. 2018;51(5). doi:1183/13993003.00692-2018
-
Wollin L et al. Eur Respir J. 2019;54(3). doi:10.1183/13993003.00161-2019
-
Hoffmann-Vold AM et al. EBioMedicine. 2019;50:379-386.
-
Selman M et al. Ann Intern Med. 2001;134(2):136-151.